Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia

Introduction There has been a growing recognition on the importance of diversity in clinical trials. Existing research has highlighted a significant demographic imbalance. Amidst this renewed focus on diversity, it is crucial to acknowledge that Asia comprises over half of the world’s population. Gi...

Full description

Saved in:
Bibliographic Details
Published in:Oncology and therapy 2024-03, Vol.12 (1), p.115-129
Main Authors: Habr, Dany, Singh, Manmohan, Uehara, Roberto
Format: Article
Language:English
Subjects:
Asia
Clinical trials
Diversity
Industry-sponsored
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Original Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction There has been a growing recognition on the importance of diversity in clinical trials. Existing research has highlighted a significant demographic imbalance. Amidst this renewed focus on diversity, it is crucial to acknowledge that Asia comprises over half of the world’s population. Given the region’s demographic significance, we sought to compare various characteristics and growth rates for trials with sites in Asia against those without any sites in Asia. Methods We performed comprehensive analyses of industry-sponsored phase 2 and 3 oncology trials registered at Clinicaltrials.gov, using drugs or biologics as investigational agents and executed between 1 January 2018 and 31 December 2022. We applied the compound annual growth rate (CAGR) as an analytical tool to track the trial growth rates over this 5-year period. Results We identified 894 industry-sponsored phase 2 and 3 cancer studies with available study location data. Out of these, 415 trials (46.42%) had study sites in Asia. Notably, these trials with sites in Asia were also more likely to be phase 3 trials (39.76% vs 6.47%, p  
ISSN:2366-1070
2366-1089
DOI:10.1007/s40487-023-00254-3